Vivos Therapeutics Announces Material Debt Reduction

LITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced that on August 31, 2026, Vivos entered into twelve exchange agreements with Streeterville Capital, LLC, exchanging $2,861,270 of outstanding principal under its secured promissory note (the "Streeterville Note") for 11,445,080 shares of common stock at an exchange price of $0.25 per share. 

As previously announced on August 4, 2026, the Company exchanged $3,250,000 of principal under the Streeterville Note for 2,500 shares of Series B Non-Convertible Preferred Stock and 1,812,031 shares of common stock.

Following these exchanges, the outstanding balance of the Streeterville Note (inclusive of fees and original issue discount) is approximately $3.7 million, as of August 31, 2026, down from the original principal amount of $8,225,000 on June 9, 2025.

The exchanges are expected to reduce the Company's liabilities and correspondingly increase stockholders' equity as the partitioned notes are surrendered and cancelled. The final amounts will be reflected in the Company's financial statements for the quarter in which each exchange settles.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the flagship DNA appliance is the first to receive clearance for treating moderate to severe OSA in children.

OSA affects an estimated one billion adults aged 30-69 years old worldwide, yet 80% or more remain undiagnosed and unaware of their condition. These chronic disorders are not just a sleep issue—they are closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes. Vivos CARE oral medical devices are designed to help address anatomical factors often associated with OSA.

Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly. A 2019 analysis published in The Lancet Respiratory Medicine estimated that approximately 936 million adults aged 30 to 69 worldwide have OSA. Through technology, education, provider partnerships and acquisitions, Vivos seeks to expand access to more comprehensive and personalized OSA diagnosis and treatment.

Vivos calls the use of its appliances and related clinical protocols to treat OSA The Vivos Method, a proprietary, clinically effective solution that is a nonsurgical, noninvasive, and nonpharmaceutical approach designed to address the complex needs of OSA patients, and which provides hope to allow patients to Breathe New Life.

For more information, visit www.vivos.com.

Cautionary Note Regarding Forward-Looking Statements

This press release, including statements of the Company's management and other parties made in connection therewith, contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning future events. Words such as "may," "would," "should," "expects," "projects," "potential," "intends," "plans," "believes," "anticipates," “hopes,” "estimates," "goal," "aim," and variations of such words and similar expressions are intended to identify forward-looking statements.

Forward-looking statements in this press release include, without limitation, statements regarding: the expected reduction of the Company's liabilities and the corresponding increase in stockholders' equity as a result of the exchanges; the anticipated surrender and cancellation of the partitioned notes; the timing and manner in which the exchanges will be reflected in the Company's financial statements; the Company's continued progress toward enhancing stockholders' equity and satisfying applicable Nasdaq continued listing requirements; and the potential for further exchanges or other reductions of the outstanding balance of the Streeterville Note.These statements involve significant known and unknown risks and are based on assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos' control. Actual results may differ materially and adversely from those expressed or implied by such forward-looking statements as a result of various factors, including, without limitation, the risks that (i) the exchanges may not reduce the Company's liabilities or increase stockholders' equity in the amounts or within the timeframe anticipated, or the accounting treatment or financial statement presentation of the exchanges may differ from the Company's expectations; (ii) the outstanding balance of the Streeterville Note may increase as a result of fees, original issue discount or other charges, or the Company may be unable to repay, refinance or further exchange the remaining balance on favorable terms or at all; (iii) the issuance of the shares of common stock in the exchanges will dilute existing stockholders, and any future exchanges or financings may result in additional dilution; (iv) the Company may not achieve or maintain compliance with applicable Nasdaq continued listing requirements, including the stockholders' equity requirement, notwithstanding the exchanges; (v) Vivos may be unable to access additional financing; and (vi) the risks described in Vivos' filings with the Securities and Exchange Commission (the "SEC"), which are available free of charge on the SEC’s website at www.sec.gov.

Except as required by applicable law, Vivos undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.

Vivos Investor Relations Contact:

Jennifer Hauser, Executive Assistant to the CEO
jhauser@vivoslife.com
720-927-3125